IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma.

urelumab (BMS-663513) - BMS, Ono Pharmaceutical

tasquinimod (ABR-215050) - Active Biotech

http://www.ncbi.nlm.nih.gov/pubmed/42082972

Adrien Denis; Arne Van der Vreken; Dewen Zhan; Eline Menu; Elke De Bruyne; Emma Verheye; Evan Calliauw; Hatice Satilmis; Helena Eriksson; Karin Vanderkerken; Kim De Veirman; Marie Törngren; Sylvia Faict

May 5, 2026